The big business behind weight-loss drugs: Global market to hit $150 billion by 2035

They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, Wegovy or Zepbound are said to be a weight-loss game changer and could drive big pharma’s revenue for years to come. But they come with a hefty price tag, while some 50 to 70 percent of people taking GLP-1s suffer side effects. Charles Pellegrin asks Frederic Bizard, a health economist and professor at ESCP Business School, who has the most to gain from this pharma revolution.